Capricor Therapeutics, Inc.
NASDAQCapricor Therapeutics enters mid-July with a widening divergence: the small-cap biotech is down 7.7% on the week to $22.22 while closely correlated peers are posting meaningful gains, and the short position is not retreating. The peer gap is the sharpest new angle this week. GERN added 14.6% over the same five sessions. DYN rose 12.1%. VKTX…
CAPR short interest surges to 31.8% of float, up 20.3% in one week as bears rebuild aggressively despite stock falling 22% over same period.
A new long-form analysis for CAPR this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumCapricor Therapeutics enters mid-July with a widening divergence: the small-cap biotech is down 7.7% on the week to $22.22 while closely correlated peers are posting meaningful gains, and the short position is not…
Snapshot as of 19 Aug 2026
Capricor Therapeutics enters the July 8 week at $22.22 — down another 7.7% over the past five sessions — with short interest back above 31% of the free float and the August 6 earnings date now less than a month…
Capricor Therapeutics closes the July 4 week at $23.21 — down 24% on the month, 24% on the week — with the short position still near multi-month highs and the August 6 earnings date drawing closer. The structural short…
Capricor Therapeutics enters the July 4 week having shed another 24% on the month to $23.21, with a fresh cluster of insider selling landing precisely as the bear thesis continues to play out. The insider activity is…
Capricor Therapeutics fell 13% on Friday to $26.44, erasing the twin weekly gains that had animated two consecutive "bears losing ground" narratives — and the short position that rebuilt so aggressively last week shows…
Capricor Therapeutics just delivered a second consecutive weekly gain, but the short position that was showing its first real cracks last week has snapped back with unexpected force. The most striking development since…
Capricor Therapeutics has delivered its sharpest weekly gain in months — up 13.3% to $28.38 — and for the first time since the bear campaign peaked, the short position is visibly retreating rather than merely…
Capricor Therapeutics heads into the weekend with a stock that bounced 3% on Friday but remains 18% below where it traded a month ago — and a short position that has stabilised rather than retreated. The bear…
Capricor Therapeutics enters the new week with a genuinely interesting tension: the bear campaign that drove short interest to multi-month highs has started to soften, but the stock keeps falling anyway. The short…
Capricor Therapeutics enters the weekend with shorts firmly in control — the stock down 11% on the week, short interest at a multi-month peak, and the borrow market tightening faster than at any point in recent…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CAPR — free to start on ORTEX.
Sign up for free →Open CAPR on ORTEX